You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. AML MutationCounter a tool to detect residual and recurrent leukemia

    SBC: Asystbio Laboratories, LLC            Topic: 102

    Abstract AsystBio LLC proposes to market a molecular tool kit called AML MutationCounter to count somatic mutations in genes that contribute to the development of acute myeloid leukemia AML We have developed a set of reagents and computer programs for application of next generation sequencing to count AML gene mutations The tool kit is versatile and can be used with either of the two major DNA ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. A Novel Hernia Mesh to Improve Anchor Point Fixation and Prevent Hernia Formation

    SBC: Deep Blue Medical Advances, Inc.            Topic: 300

    Abstract Two million laparotomies are performed annually in the U S with ventral hernia being a frequent complication in of patients The average cost patient for each hernia operation in the U S in was $ which amounts to $ billion annually The ten year ventral hernia recurrence rate is There are $ B in hernia meshes sold annually in the United States With ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. A novel product for tendinopathy treatment

    SBC: NEW YORK R&D CENTER FOR TRANSLATIONAL MEDICINE AND THERAPEUTICS, INC.            Topic: NIA

    Project Summary This study aims to prove the concept and feasibility that TendonCure extracellular vesicles that contain signaling molecules i e exosomes secreted by mesenchymal stem cells i e tendon stem progenitor cells TSPCs or adipose derived stem cells ADSCs from individual patients donors cultured on a novel scaffold exert therapeutic efficacy on tendinopathy when injected into ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. A Novel Scaffold to Promote Skin Regeneration

    SBC: FirstString Research, Inc            Topic: NIAMS

    PROJECT SUMMARY Dermal scarring affects more than million people worldwide annually over million people are injured in motor vehicle accidents over million patients are severely burned and thousands of warriors are wounded in military blasts In severe burns more than of patients develop hypertrophic scar contraction which leads to hypertrophic scar contractures HSc HSc a ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Artificial neural networks for high performance fully automated particle tracking analysis even at low signal to noise regimes

    SBC: AI Tracking Solutions LLC            Topic: 400

    Abstract Particle tracking PT is a powerful biophysical tool for elucidating molecular interactions transport phenomena and rheological properties in complex biological environments Unfortunately PT remains a niche tool in life and physical sciences with a limited user base in large part due to significant time and technical constraints in extracting accurate time variant positional data fr ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Creation of animal models of mitochondrial DNA disease for translational research applications

    SBC: Enzerna Biosciences LLC            Topic: 400

    Mitochondria are the principal generators of cellular ATP by oxidative phosphorylation which links electron transport via Complexes I through IV to production of ATP via ATP synthase Over pathogenic human mitochondrial DNA mtDNA mutations associated with diseases ranging from cardiomyopathy to juvenile blindness have been identified Collectively millions are affected by mtDNA disease fo ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Development and in vitro validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of an Antigen Capture Assay for Babesia microti

    SBC: Biopeptides, Corp            Topic: NIAID

    DESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a New Carbohydrate based Anticoagulant Drug

    SBC: Glycan Therapeutics LLC            Topic: NHLBI

    Low molecular weight heparins LMWHs a commonly used anticoagulant drug in the hospitals are carbohydrate based molecules Heparin is isolated from porcine intestine through a long and unreliable supply chain LMWH is a depolymerized product of heparin A worldwide distribution of contaminated heparin in impacting the purity and safety of LMWHs was associated with deaths in the US Th ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a POEGMA Aptamer rapid onset anticoagulant that eliminates antigenicity to anti PEG antibodies

    SBC: Gateway Bio, Inc.            Topic: NHLBI

    ABSTRACT The objective of this STTR proposal is to reformulate a promising PEG aptamer rapid onset anticoagulant ROA by applying a novel PEG like POEGMA polymer brush technology capable of eliminating anti PEG antigenicity The importance of this proposal is highlighted by the early termination of a recent Phase III clinical trial of the original PEG aptamer conjugate in which severe allergic ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government